Metoclopramide in gastrooesophageal reflux

C. STANCIU AND JOHN R. BENNETT

From the Gastrointestinal Unit, Hull Royal Infirmary

SUMMARY In 30 patients with gastrooesophageal reflux, intravenous metoclopramide (Maxolon) has been shown to increase the gastrooesophageal sphincter pressure. The rise is dose-related until a maximum pressure, proportional to the resting sphincter tone, is reached. The effect is reversed by atropine. Peristaltic waves are increased in pressure by metoclopramide.

In 18 patients with gastrooesophageal reflux intravenous metoclopramide diminished the frequency of reflux episodes and increased the rate at which the oesophagus emptied itself of an acid load.

Metoclopramide (Maxolon) has been shown to have a number of actions on gastrointestinal motility but little attention has been paid to its effects on the oesophagus. The one detailed study published (Heitmann and Møller, 1970) clearly demonstrates that in healthy adults the drug raises the pressure of the gastrooesophageal sphincter and increases the height and duration of peristaltic contractions in the distal oesophagus. An obvious potential application of these actions is to prevent gastrooesophageal reflux, and we have studied its effect in patients with symptoms of 'reflux oesophagitis'.

Apparatus

Intraluminal pressures were recorded through two polyethylene catheters (internal diameter 1-2 mm) each with a single side hole, the openings being set 5 cm apart. The catheters were continuously perfused with distilled water at 0·8 ml/min by a constant infusion syringe pump and were connected to Bell and Howell transducers.

Intraluminal pH was measured by a Radiometer combined glass and reference electrode (GK 282C) with Radiometer pH meter (type PHM 26) which was standardized before each test. The output of transducers and pH meter was recorded on a Devices M 19 multichannel direct writing recorder. Respiration was recorded by a belt pneumograph.

The Effect of Metoclopramide on Gastrooesophageal Motility

METHODS

Gastrooesophageal sphincter pressures were studied in 16 men and 14 women aged 18 to 77 years (mean 51·2 years) with symptoms of gastrooesophageal reflux (heartburn, acid regurgitation, and discomfort on drinking hot fluids). Radiologically eight had been shown to have a hiatus hernia and 11 gastrooesophageal reflux, and all had abnormal gastrooesophageal reflux detected by 15-hour intraoesophageal pH recordings (Stanciu and Bennett, to be published). Three patients had previously had truncal vagotomy and pyloroplasty for duodenal ulceration.

Recordings were made with the patients supine by withdrawing the previously swallowed tube assembly from the stomach to oesophagus in 0·5 cm steps. At each point in the oesophagus, pressures were recorded both during quiet breathing and during swallows. In 20 patients the procedure was repeated after the intravenous injection of 5 ml 0·9% sodium chloride solution, and again after 10 mg metoclopramide intravenously. The patients were not aware which injection contained the drug, but had previously given consent to the study.

In another 10 patients the solutions were given by continuous intravenous infusion while the distal catheter opening was held in the gastrooesophageal sphincter. At first, 0·9% sodium chloride was infused and then metoclopramide (40 mg/100 ml saline) at increasing rates. The infusion was continued at each rate for five to six minutes. In six of these patients atropine (0·3 mg/kg) was given intravenously at the end of the metoclopramide infusion.

RESULTS

The mean resting end-expiratory gastrooesophageal sphincter pressure (average of recorded pressure in all patients) before metoclopramide was 11·8 ± SD 5·7 cm water. There was no significant change after
Fig 1 Change in gastrooesophageal sphincter pressure induced by intravenous injections of normal saline or 10 mg metoclopramide.

Fig 2 Recording of intraluminal pressures, from perfused open-tip tubes 5 cm apart, during withdrawal in the same patient before and after metoclopramide, 10 mg. The 'pressure profile' of the gastrooesophageal sphincter is shown in the middle trace. After metoclopramide the peak sphincter pressure rises but relaxation on swallowing is unimpaired. The upper trace demonstrates the increased height of peristaltic waves after metoclopramide.

Fig 3 Relationship between basal gastrooesophageal sphincter pressure and the rise induced by 10 mg intravenous metoclopramide.
administration of intravenous saline, but intravenous metoclopramide invariably raised the pressure (fig. 1). The mean pressure after metoclopramide was 20.8 ± 9.7 cm water, a significant rise (P < 0.01). The length of the sphincter did not change, and relaxation on swallowing was unimpaired (fig. 2). The rise induced by 10 mg metoclopramide was from 2 to 23 cm water and the rise was proportional to the resting pressure (fig. 3). The effects were equally marked in patients after vagotomy. During intravenous infusions at increasing rates the pressure rose within seconds of each increment until it reached a plateau beyond which further increments would not raise it (fig. 4). Atropine produced a marked fall in sphincter pressure, even while the metoclopramide effect was still present, usually reducing it below the resting tone (fig. 5).

Resting pressure in the gastric fundus and in the body of the oesophagus did not change after metoclopramide. However the mean pressure of peristaltic contractions was increased from 38.7 ± SD 7.2 to 43 ± 7.1 cm water by metoclopramide (P < 0.01). The duration and speed of propagation of peristaltic waves was increased, but not by significant amounts, and the proportion of synchronous and spontaneous contractions was unchanged.

**DISCUSSION**

The precise mechanism of metoclopramide's actions on the gut is not yet determined but its probable direct effects on smooth muscle cells (Hukuhara, Nakayama, Fukuda, and Neya, 1966; Coulland and Levêque, 1966) may be due to increased sensitivity to acetylcholine (Eisner, 1968).

Our observations first confirm those of Heitmann and Möller (1970) in showing a selective increase in lower oesophageal sphincter pressure after intravenous metoclopramide, without altering gastric fundal pressures. We further showed that this effect is dose-related; successive increments in dose raised the pressure until a maximum pressure was reached.
Both the incremental rises in pressure, and the final maximum 'plateau' pressure, are proportional to the original resting pressure of the sphincter.

Our studies on patients after vagotomy indicate that the effects of metoclopramide on the gastro-oesophageal sphincter do not depend on an intact vagus nerve, but the inhibitory action of atropine suggests that it may act via the intramural cholinergic neuromuscular apparatus.

The Effect of Metoclopramide on Gastro-oesophageal Reflux

METHODS

Acid clearance was performed in 18 patients (eight men and 10 women, mean age 54.4) and reflux test in 16 patients (seven men and nine women, mean age 52.2) known to have gastrooesophageal reflux, before and after a bolus injection of 10 mg intravenous metoclopramide.

The electrode was placed 5 cm above the gastro-oesophageal sphincter. The manometric catheters were withdrawn above the electrode, and the continuous perfusion pump was stopped. With the patient supine 15 ml 0.1N hydrochloric acid was introduced through the proximal catheter 10 cm above the electrode, and the patient was instructed to swallow every 30 seconds. The number of swallows necessary to raise the lower oesophageal pH from 1.5 to 6 was then counted.

Reflux test
The manometric catheters were introduced into the stomach and 250 ml 0.1N hydrochloric acid was instilled. The catheters were flushed with a little water and air and then withdrawn above the pH electrode. The patient then performed a series of manoeuvres—deep breathing, Valsalva, Muller, coughing—while lying supine, on the right side and on the left side, and supine with 15° head-down tilt. The pH was recorded continuously 5 cm above the gastrooesophageal sphincter.

Statistical methods
Results before and after metoclopramide have been compared by the Wilcoxon matched pair signed rank test.

RESULTS

Acid clearing (fig. 6)
The mean number of swallows to raise the lower oesophageal pH to 6 was 16.3 ± SD 5.6 before and 13.5 ± 4.3 after metoclopramide. The difference is significant (p < 0.01).

Reflux (16 patients)
Before metoclopramide all patients showed gastro-oesophageal reflux after some manoeuvres. After metoclopramide no reflux was detected in six patients. In all the remaining 10 patients the number of manoeuvres which caused reflux was diminished (p < 0.01) (fig. 7).

DISCUSSION

This study shows that metoclopramide has the useful effect, in patients who suffer from gastro-oesophageal reflux, of markedly diminishing the frequency of episodes of reflux; moreover it increases the rate at which the oesophagus rids itself of acid contents. The likely methods by which metoclopramide achieves this result were demonstrated in the previous paper. The rise in tone of the lower oesophageal sphincter presumably assists in
Metoclopramide in gastrooesophageal reflux

Fig. 7 Number of reflux episodes during standard manoeuvres before and after 10 mg intravenous metoclopramide.

preventing reflux, while the increased pressure of peristaltic contractions may assist oesophageal emptying. Our findings conflict with those of Glanville and Walls (1972) who, using standard radiological techniques, found that intravenous metoclopramide failed to change the incidence of gastrooesophageal reflux during barium meal examinations. The reason for the difference probably lies in the methodology. Radiology has been shown to be an imprecise tool for demonstrating gastrooesophageal reflux (Piccone, Gutelius, and McCorriston, 1965; Skinner and Booth, 1970); short-term changes in degree of reflux require more sensitive techniques for their demonstration.

Our results are all in short-term experiments using intravenous administration. It remains to be shown whether metoclopramide, given regularly by mouth, is equally effective, and studies to demonstrate this are in progress.

The nursing staff of the Hull Royal Infirmary Gastrointestinal Unit gave great assistance in caring for the patients.

Beecham's Laboratories Ltd generously contributed the Maxolon used in the study. The invaluable technical help of Mr J. Holman was financed by the Wellcome Foundation. Carol Stanciu is the recipient of a research grant from the Leeds Regional Hospital Board.

References


Metoclopramide in gastrooesophageal reflux

C. Stanciu and John R. Bennett

*Gut* 1973 14: 275-279
doi: 10.1136/gut.14.4.275

Updated information and services can be found at:
http://gut.bmj.com/content/14/4/275

**Email alerting service**

These include:
Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/